Results 21 to 30 of about 165,965 (304)

GLP-1 Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Kidney Disease

Kidney and Dialysis, 2022
Diabetic kidney disease (DKD) represents an important diabetes (DM) complication associated with significant impacts on morbidity, mortality, and quality of life. Recent evidence from cardiovascular and kidney outcome trials has dramatically impacted the
Joshua J. Neumiller, Radica Z. Alicic, Katherine R. Tuttle   +2 more
doaj   +1 more source

The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update [PDF]

Endocrinology and Metabolism
Obesity is the fifth leading risk factor for global deaths with numbers continuing to increase worldwide. In the last 20 years, the emergence of pharmacological treatments for obesity based on gastrointestinal hormones has transformed the therapeutic ...
Agnieszka Jakubowska, Carel W. le Roux, Adie Viljoen   +2 more
doaj   +1 more source

Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials

British medical journal, 2021
Objective To evaluate sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists in patients with type 2 diabetes at varying cardiovascular and renal risk. Design Network meta-analysis.
S. Palmer, B. Tendal, R. Mustafa, P. Vandvik, Sheyu Li, Q. Hao, David J. Tunnicliffe, M. Ruospo, P. Natale, V. Saglimbene, A. Nicolucci, David W. Johnson, M. Tonelli, M. Rossi, S. Badve, Yeoungjee Cho, Annie-Claire Nadeau-Fredette, M. Burke, L. Faruque, Anita M. Lloyd, Nasreen Ahmad, Yuanchen Liu, Sophanny Tiv, Tanya Millard, L. Gagliardi, N. Kolanu, Rahul D Barmanray, Rita McMorrow, Ana Karina Raygoza Cortez, H. White, Xiang Chen, Xu Zhou, Jiali Liu, Andrea Flores Rodríguez, A. D. González-Colmenero, Yang Wang, Ling Li, S. Sutanto, Ricardo Cesar Solis, Fernando Diaz Gonzalez-Colmenero, R. Rodríguez‐Gutiérrez, M. Walsh, G. Guyatt, G. Strippoli   +43 more
semanticscholar   +1 more source

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.

The Lancet Diabetes and Endocrinology, 2019
BACKGROUND Glucagon-like peptide-1 (GLP-1) receptor agonists differ in their structure and duration of action and have been studied in trials of varying sizes and with different patient populations, with inconsistent effects on cardiovascular outcomes ...
S. Kristensen, R. Rørth, P. Jhund, K. Docherty, N. Sattar, D. Preiss, L. Køber, M. Petrie, J. McMurray   +8 more
semanticscholar   +1 more source

Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma?

Frontiers in Neuroscience, 2022
Glaucoma is a common ocular neurodegenerative disease characterized by the progressive loss of retinal ganglion cells and their axons. It is the most common cause of irreversible blindness.
Zaynab Ahmad Mouhammad, Rupali Vohra, Rupali Vohra, Anna Horwitz, Anna-Sophie Thein, Jens Rovelt, Barbara Cvenkel, Barbara Cvenkel, Pete A. Williams, Augusto Azuara-Blanco, Miriam Kolko, Miriam Kolko   +11 more
doaj   +1 more source

Beyond Simple Mimicry: Next‐Generation Geometric Architectures and Future Paradigms in Small‐Molecule and Macrocyclic Peptidomimetics

Angewandte Chemie, EarlyView.
Peptide‐to‐Small Molecule Paradigm: Peptidomimetics have evolved from simple mimicry toward drug‐like scaffolds supported by increasing clinical successes. This Perspective highlights the geometric design principles—linear repetition, convergent fusion, and cyclization—defining the next‐generation peptidomimetic architectures capable of targeting ...
Jesang Lee, Sumin Son, Jeong Yeon Yoo, Ji Hyae Lee, Meehyun Chun, Seung Bum Park   +5 more
wiley   +2 more sources

Adverse effects of GLP – 1 Receptor Agonists

Journal of Education, Health and Sport
Introduction and purpose Glucagon-like peptide-1 receptor agonists (GLP – 1 RAs) are indicated in type 2 diabetes (T2D) and obesity because of their high efficacy in controlling blood glucose levels and inducing weight loss.
Anna Kasprzak, Monika Kułaga, Monika Grzybek, Diana Mazur-Lesińska, Barbara Szostak, Sylwia Wielgosz-Biała, Krzysztof Tyszkiewicz, Borys Łozowski, Małgorzata Kasprzak, Barbara Wilczyńska   +9 more
doaj   +1 more source

Harnessing the Reactivity of Sulfinate Salts With Cystine: An Umpolung Approach to Residue‐Specific Peptide Modification

Angewandte Chemie, EarlyView.
While cysteine is widely employed as a nucleophilic handle for peptide modification, the electrophilicity of the oxidized form, cystine, is rarely exploited. This study describes a mild, photochemical coupling of sulfinate salts with peptide disulfides.
Joshua M. Hammond, Esteban Suárez‐Picado, Lena von Sydow, Hanna Bruss, Laurent Knerr, Magnus Johansson, Anaïs Noisier, Lara R. Malins   +7 more
wiley   +2 more sources

Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity

JAMA Network Open
Key Points Question What are the rates of and factors associated with discontinuation and subsequent reinitiation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among adults with overweight or obesity?
Patricia J. Rodriguez, Vincent Zhang, Samuel Gratzl, Duy Do, Brianna M. Goodwin Cartwright, Charlotte Baker, Ty J. Gluckman, N. Stucky, Ezekiel J Emanuel   +8 more
semanticscholar   +1 more source

Structure and dynamics of semaglutide- and taspoglutide-bound GLP-1R-Gs complexes

Cell Reports, 2021
Summary: The glucagon-like peptide-1 receptor (GLP-1R) regulates insulin secretion, carbohydrate metabolism, and appetite and is an important target for treatment of type 2 diabetes and obesity. Multiple GLP-1R agonists have entered into clinical trials,
Xin Zhang, Matthew J. Belousoff, Yi-Lynn Liang, Radostin Danev, Patrick M. Sexton, Denise Wootten   +5 more
doaj   +1 more source